Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.53 -11.4% 11.85 9,369,261 16:21:46
Bid Price Offer Price High Price Low Price Open Price
11.70 12.00 13.375 11.70 13.375
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -3.17 -2.10 16
Last Trade Time Trade Type Trade Size Trade Price Currency
16:55:41 O 250,000 11.707 GBX

Evgen Pharma (EVG) Latest News (1)

More Evgen Pharma News
Evgen Pharma Investors    Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date Time Title Posts
26/10/202022:17Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer4,723
27/9/202020:50Evgen Pharma Plc Investor Presentation1
27/9/202020:50Interview and Q&A with Evgen Pharma13
27/9/202020:50TimboisabЂllend14
13/6/201708:45Evgen Pharma Interview-

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:57:3411.71250,00029,267.50O
16:57:3211.71250,00029,267.50O
16:56:2312.2025,9913,170.90O
16:56:1312.2525,0003,062.50O
16:56:0312.5018,1832,272.88O
View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

DateSubject
26/10/2020
08:20
Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 13.38p.
Evgen Pharma Plc has a 4 week average price of 10.85p and a 12 week average price of 10.85p.
The 1 year high share price is 16.88p while the 1 year low share price is currently 2.75p.
There are currently 137,297,441 shares in issue and the average daily traded volume is 3,937,071 shares. The market capitalisation of Evgen Pharma Plc is £16,269,746.76.
25/10/2020
09:34
kingalf: As results ars not expected until September 2021 another share placing is inevitable to strengthenthe balance sheet. My personal view is that it will happen sooner rather than later and the likes of FinnCap will help organise it. You might be interested in comments from the last issue , funds remaining on the balance sheet back then are now back to todays levels which is why I think it will happen very soon, hence the non advancement of the share price. EVGEN PHARMA SET FOR MULTIMILLION-POUND PLACING 8 May 2019 North West Deals Matthew Ord Evgen Pharma set for multimillion-pound placing Clinical stage drug development company Evgen Pharma, which has operations in Cheshire and Liverpool, is set to secure £5m through a further share placing. At the company's latest general meeting, all resolutions were passed. This included plans – as revealed in April – to raise the money through two placings of 13,057,489 and 20,275,840 shares on AIM. The first tranche was submitted on 18 April, with the remainder of the £5m set to be secured today (9 May). Evgen will use the net funds to strengthen the balance sheet for future partnering, develop product formulation for use in STEM II and other investigator-led clinical studies, and conduct further toxicology studies that will remove current restrictions on the duration of clinical trial treatment phases. At the time the proposals were originally announced, chief executive Stephen Franklin said: "The funds strengthen the company's balance sheet following the recent announcement of the successful final read-out of our phase II STEM clinical trial in breast cancer and ahead of the final read-out of our phase II SAS clinical trial in subarachnoid haemorrhage. "The additional funds will enable us to further progress our development work whilst also supporting business development and out-licensing activities." FinnCap and WG Partners both worked on the deal.
24/10/2020
20:38
moneymunch: I'm not posting misinformation , I'm merely speculating on Evgen's prospects and potential on the the Evgen share forum, you on the other hand spend your time promoting another stock on the EVG thread and try undermine Evgen's prospects in the process....SFX-01's patient trials start next week and in my humble opinion , early reporting is highly likely, you don't like that idea incase EVG has the march on SNG, although I personally hope both do well as I'm sure there will be more than one treatment available for Covid-19 in the coming months....early reporting very likely imho or do yo you think the trial would continue to September 2021 if no therapeutic benefit was observed or recorded after the phase 2 stage of the trial...the investigators will be closely monitoring and collecting all data on patient welfare of those on SFX-01 and the placebo....Gl....anyone would think that you're worried about SFX-01 will be successful, why would that be when you know it all and have stated that SFX-01 will never be approved for the treatment of Covid-19 ?????????? ;-)
24/10/2020
19:14
moneymunch: This sums the know it all up ...and why he spends so much on time on the EVG thread promoting SNG and undermining EVG....if SFX-01 isn't working then the trial will be discontinued...if it is working then EVG's share price goes into orbit...investigators will know early on if it is or not, placebo or no placebo because of the clinical data will be collected from each patient administered SFX-01 and the placebo....and their general health and condition will be observed after 15 days...Gla :-) EVGNobbygnome - 19 Sep 2020 - 10:00:10 - 3773 of 4361 >> MM I haven't laughed so much for ages. SFX-01 a competitor for SNG001? That is such a completely ridiculous statement. I will put my head above the parapet and say that IMHO SFX-01 will never be approved for use in Covid 19 patients. Meanwhile SNG001 easily has the best data in Covid 19 patients from a placebo controlled trial......
23/10/2020
06:01
moneymunch: RNS Number : 9767C Evgen Pharma PLC 23 October 2020 Evgen Pharma plc ("Evgen" or the "Company") All approvals received for STAR trial to commence Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, is pleased to announce that all necessary regulatory approvals have now been received for the STAR trial (SFX-01 treatment for Acute Respiratory Infections). Trial recruitment is expected to commence around the end of the month. STAR is a Phase II/III trial to investigate whether the company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") in patients with suspected COVID-19. Patients may therefore be drawn from both hospital and community settings and may present with COVID-19 or other respiratory diseases. It is a randomised, placebo-controlled trial and is sponsored by the University of Dundee. SFX-01 upregulates the Nrf2 pathway which is part of the natural human defence against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. Preclinical studies have shown that up-regulating the Nrf2 pathway reduces the severity of ARDS, the progressive lung damage observed in COVID-19 and pneumonia patients, which can result in the need for invasive ventilation in an intensive care unit. The clinical study is being supported by a grant from LifeArc, as previously announced in June 2020, and is being led by Professor James Chalmers, British Lung Foundation Professor of Respiratory Research at the University of Dundee. The results are expected in 2021. Evgen will supply clinical centres with SFX-01 and a placebo as its contribution to the trial. No additional financing is required as the costs of providing SFX-01 for the trial are not material. Dr Huw Jones, Evgen CEO, commented: "Receiving full regulatory approval is a significant step forward for us. We look forward to the start of recruitment for the trial shortly with our partner. We hope that the outcome of this trial will lead to an additional treatment for COVID-19 patients and that SFX-01 could play a big part in managing the current pandemic."
21/10/2020
17:41
moneymunch: I only post about SNG in reply to those that continually try and promote it on the EVG thread, and very often those that do, generally try and undermine EVG at the same time. Initially, i held SNG as an example of what could happen here, and still do, but for some reason a few at SNG seem unhappy or uneasy that EVG could follow suit. Anyways I reckon EVG is one on the most underated stocks given the potential at hand on all things Sulphorphane, STAT3 and NRF2, and fairly certain that a strategic investor and/or JV is looming. Evg had outstanding phase 2 results for breast cancer ( far more extensive than SNG's phase 2 Covid-19 results, for instance) and now have phase 2 and phase 3 for Covid-19, not to mention the rest of the disease targets in CKD, NASH and Autism etc, and Jim Mellon....the majority of other Bio's with similar stage pipelines are worth many £lmillions more, and so the Transformational upside opportunity is firmly in our favour imho...Exciting times ahead!!! Gl :-)
19/10/2020
21:00
gimmetheloot: RE: SFX-0117 Oct 2020 21:44 Interesting tweet from Pro Dillon at University of Dundee, who has had SFX-01 under evaluation for clinical trials for NASH since December 2019.....maybe news could be close. Gla ;-) John Dillon Retweeted Journal of Hepatology @JHepatology · Oct 15 Reliability of hepatopathologists’ liver #biopsy evaluation using currently accepted criteria is suboptimal and has major implications for #NASH clinical trials. http://bit.ly/31s8nvK ........................ 5/12/19 Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine. With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation. Non-alcoholic fatty liver disease ("NAFLD") is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population. NAFLD represents a spectrum of phenotypes ranging from simple steatosis (fatty infiltration), through NASH to cirrhosis. Approximately 30% of adults in the general population have NAFLD, and 10%-20% of these have NASH. Amongst patients with NASH, 20-30% are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years. In view of the tens of thousands of individuals who are likely to develop NASH in the next decade, it is clear that this disease will represent a major burden to healthcare in the UK. Professor John Dillon and colleagues have previously published research that showed that drug-induced activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigated against NASH and liver fibrosis. On this basis, Professor John Dillon approached Evgen, the developer of SFX-01, a development stage drug that is known to activate the Nrf2 pathway and has demonstrated excellent safety and tolerability in previous clinical trials. John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to
17/10/2020
19:05
moneymunch: Interesting tweet from Pro Dillon at University of Dundee, who has had SFX-01 under evaluation for clinical trials for NASH since December 2019.....maybe news could be close. Gla ;-) John Dillon Retweeted Journal of Hepatology @JHepatology · Oct 15 Reliability of hepatopathologists’ liver #biopsy evaluation using currently accepted criteria is suboptimal and has major implications for #NASH clinical trials. hTtp://bit.ly/31s8nvK ........................ 5/12/19 Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine. With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation. Non-alcoholic fatty liver disease ("NAFLD") is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population. NAFLD represents a spectrum of phenotypes ranging from simple steatosis (fatty infiltration), through NASH to cirrhosis. Approximately 30% of adults in the general population have NAFLD, and 10%-20% of these have NASH. Amongst patients with NASH, 20-30% are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years. In view of the tens of thousands of individuals who are likely to develop NASH in the next decade, it is clear that this disease will represent a major burden to healthcare in the UK. Professor John Dillon and colleagues have previously published research that showed that drug-induced activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigated against NASH and liver fibrosis. On this basis, Professor John Dillon approached Evgen, the developer of SFX-01, a development stage drug that is known to activate the Nrf2 pathway and has demonstrated excellent safety and tolerability in previous clinical trials. John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology."
27/9/2020
14:17
moneymunch: As well as the status of SFX-01's patient trials , more news from Unversity of Dundee also expected. Gla ;-) Active Defining the Oxidative Stress-Related Mechanisms by which Activation of the Transcription Factor Nrf2 Arrests and Resolves Liver Fibrosis Arthur, S., Dillon, J., Dinkova-Kostova, A., Hayes, J. & Henderson, C. Medical Research Council 1/04/20 → 31/03/24 Project: Research Funding Medical Research Council (MR/T014644/1): £2,428,412.00 5/12/19 Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine. With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation. Non-alcoholic fatty liver disease ("NAFLD") is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population. NAFLD represents a spectrum of phenotypes ranging from simple steatosis (fatty infiltration), through NASH to cirrhosis. Approximately 30% of adults in the general population have NAFLD, and 10%-20% of these have NASH. Amongst patients with NASH, 20-30% are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years. In view of the tens of thousands of individuals who are likely to develop NASH in the next decade, it is clear that this disease will represent a major burden to healthcare in the UK. Professor John Dillon and colleagues have previously published research that showed that drug-induced activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigated against NASH and liver fibrosis. On this basis, Professor John Dillon approached Evgen, the developer of SFX-01, a development stage drug that is known to activate the Nrf2 pathway and has demonstrated excellent safety and tolerability in previous clinical trials. John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology." 16/7/20 Metabolic Associate steatohepatitis (MASH) Metabolic associated fatty liver disease (MAFLD) is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population 10%-20% of those with MAFLD have MASH and 20-30% of MASH patients are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years Professor John Dillon (University of Dundee) showed that activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigate against MASH and liver fibrosis. MoU with the University of Dundee to supply SFX-01 for a potential clinical trial in MASH Option to license the clinical data to enable subsequent development/commercialisation of SFX-01 in MASH and liver fibrosis
24/9/2020
06:02
moneymunch: RNS Number : 9223Z Evgen Pharma PLC 24 September 2020 Evgen Pharma Plc ("Evgen" or "the Company") Appointment of Chief Executive Officer Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and other conditions, announces that Huw Jones PhD will be joining the Board as Chief Executive Officer in early October. Dr Jones has over 30 years' experience of leadership roles in public and private R&D-based companies within the biotechnology and pharmaceutical sector, with a particular focus on pre-clinical and clinical drug development, dilutive and non-dilutive financing and business development. He is Chairman of Chronos Therapeutics Ltd, Non-Executive Director of Rexgenero Ltd and Strategic Advisor to Gen2 Neuroscience Ltd. Dr Jones holds a PhD in pharmacology from the University of Birmingham, UK. Barry Clare, Chairman of Evgen commented: "The Board is delighted to appoint Huw as our new CEO as we work together to deliver the undoubted potential of SFX-01. We believe that SFX-01 has significant value across a range of diseases including cancer and respiratory diseases such as COVID-19." Commenting on his appointment, Huw Jones said: "I am honoured to join the Board of Evgen at such an exciting time and to working with Board colleagues, management and partners to realise the promise of SFX-01. I've been impressed by the focus and commitment of my new colleagues and look forward to working with them towards providing a new treatment for patients with high unmet medical needs." The following information regarding the appointment of Dr Huw Jones (aged 60) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies: Current directorships and/or partnerships Daffodil Consulting LLP Chronos Therapeutics Limited Rexgenero Limited In accordance with Schedule 2(g) v, Dr Jones was CEO of Ardana Plc at the time of its administration in June 2008. There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies. The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014
15/9/2020
06:02
moneymunch: RNS Number : 9626Y Evgen Pharma PLC 15 September 2020 Evgen Pharma plc ("Evgen" or the "Company") Licence agreement with Juvenescence for non-pharmaceutical applications $10.5m milestones plus royalties on sales Evgen Pharma plc (AIM: EVG), the clinical-stage drug development company, is pleased to announce the licensing of its sulforaphane stabilisation technology in a number of non-pharmaceutical applications to Juvenescence Ltd ("Juvenescence"). In particular, Juvenescence intends to market and sell a high-end nutritional health product containing a defined dose of sulforaphane extracted from natural sources. Under the terms of the license agreement ("the Agreement"), Evgen will receive milestone and option payments of up to $10.5m as detailed below. Evgen will also receive royalties on future product sales. This agreement monetises one element of Evgen's sulforaphane technology platform within a timescale considerably shorter than that typical of pharmaceutical development. Evgen's focus will remain on progressing its therapeutic programmes, and the Agreement contains provisions which ensure a clear differentiation between potential nutritional health products and pharmaceutical products, including limitations on daily dose. Juvenescence will deploy the Sulforadex® stabilisation technology to manufacture and market a nutritional health product containing a defined and stable dose of sulforaphane, derived from natural sources. This contrasts with the synthetic sulforaphane which is used in SFX-01, the Company's lead therapeutic product. It is envisaged that product launch by Juvenescence will occur within the next two years. About Juvenescence (www.juvenescence.ltd) Juvenescence is a life sciences company based on a completely new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies, focused on increasing how long people live in health by preventing the diseases of aging in the first place. JuvLife, a division of Juvenescence, is focused on the development and commercialisation of scientifically proven and branded nutritional health products and medical foods that can improve human longevity and quality of life. Details of the Agreement The license is for exclusive rights to exploit certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and the Rest of the World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales. Evgen received an initial payment of $250k on signing of the Agreement. Barry Clare, Executive Chairman of Evgen, said: ''This deal is a strong demonstration of the broad potential for our sulforaphane platform and achieves monetisation in an area which is outside our focus of therapeutic development in the Nrf2 and STAT3 pathways. Juvenescence has a science-driven approach to nutritional health products and brings in-depth experience in this sector. We are delighted to have them as a partner. '' Colin Watts, Chief Executive Officer of JuvLife Division, said: "We are pleased to reach an agreement with Evgen to leverage their scientific technology and expertise to create a differentiated and innovative new product for the global consumer nutritional health market. Juvenescence has built a reputation as a broad-based healthcare company in the Longevity space through strong partnerships with scientific leaders in their specific areas and we are delighted to have such a partner in Evgen.''
Evgen Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201026 22:52:32